Combining CTC Analysis and Proteomics Reveals New Insights into Metastatic Breast Cancer
A breakthrough prospective study has demonstrated how combining live circulating tumour cells (CTCs) captured from a blood sample with advanced blood protein profiling can help doctors monitor treatment response and disease progression.
Published in the Journal of Experimental & Clinical Cancer Research (2026)[1], this landmark research study marks a major new frontier in oncology. It showcases how a multilayered liquid biopsy approach can transform the monitoring and management of advanced breast cancer.
Tracking the Systemic Immunovascular Signature
The study evaluated a cohort of 60 patients at the time of stage 4 breast cancer diagnosis, prior to initiating treatment. By pairing CTC detection with high-throughput proteomic analysis from a simple blood sample, researchers investigated the complex relationships between cellular dissemination, systemic immune regulation, and clinical outcomes.
Unlike traditional tissue biopsies that require surgical intervention, this multidimensional approach combines cellular tracking with Olink’s advanced Proximity Extension Assay (PEA) technology. By simultaneously quantifying 92 plasma proteins related to immune regulation, inflammation, and blood vessel remodelling, the researchers uncovered a distinct systemic profile. The findings reveal that metastatic breast cancer operates as a highly coordinated immunovascular disease, where escaping cancer cells trigger a systemic inflammatory environment that rewires the host’s immune system to favour tumour survival.
How Disseminated Cells Evade the Immune System
By pairing proteomics with cellular detection, the study uncovered exactly how escaping cancer cells protect themselves in the bloodstream. Patients with high CTC burdens showed a direct enrichment of immunomodulatory and pro-metastatic proteins, including IL-8, HGF, and galectin-9, a profile that directly correlates with systemic immunosuppression.
Concurrently, cellular analysis revealed a sharp increase in suppressive regulatory T cells (Tregs) and alternatively activated M2-like monocytes, which effectively camouflage the travelling tumour cells. Meanwhile, critical anti-tumour effectors, including killer T cells and natural killer (NK) cells, exhibited features of functional exhaustion, indicating a severely compromised capacity to mount an effective anti-cancer response.
Driving the Frontier of Precision Oncology
The ultimate power of this multi-omic approach lies in its clinical and translational utility. The study identified two standout circulating biomarkers that act as independent, early warning indicators of rapid disease progression.
While blood-based protein profiling provides a comprehensive snapshot of systemic disease biology, isolating viable CTCs provides direct access to the metastatic seeds themselves. This integration creates unprecedented opportunities for downstream molecular, genomic, and functional analyses to uncover the exact mechanisms driving drug resistance.
As drug developers increasingly seek predictive and pharmacodynamic biomarkers, platforms that enable the recovery of intact CTCs alongside deep plasma proteomics will become indispensable to translational research. Moving forward, combining live-cell analysis with proteomic readouts promises to accelerate biomarker discovery, optimise clinical trial design, and support the development of highly tailored cancer therapies.
This study shows that the future of oncology lies in combining live-cell isolation with other advanced analytics. To turn this research into a scalable clinical reality, Vortex Liquid Biopsy Solutions offers a technological bridge. Our automated VTX-1 Liquid Biopsy System uses label-free microfluidics to isolate intact, highly viable CTCs directly from blood samples. By preserving the cells’ natural state, Vortex provides the right sample quality necessary to fuel the deep research and biomarker discovery that will define the next generation of personalised cancer care.
